Back to results
US 6,274,305 B1Granted
Inhibiting proliferation of cancer cells
AssigneeTufts University
InventorsCarlos Sonnenschein, Ana M. Soto
Life of this patent
Estimating the term…
Abstract
A method of testing cancer cells is described. Assays are provided for determining the potential for inhibiting cancer cells proliferation using albumin-derived peptides. The methods of the present invention allow for drug screening as well as for evaluation of biopsied tumors.
Claims13
A method of measuring human cancer cell proliferation, comprising:
- a) providing:
- i) a human cancer patient,
- ii) an albumin-derived peptide, wherein said albumin-derived peptide is truncated in length, thereby shorter than the 585 amino acid long human serum albumin, and comprises domains I and II of human serum albumin;
- b) obtaining cancer cells from said patient;
- c) culturing said cancer cells in serum-free media;
- d) contacting said cells ex vivo with said albumin-derived peptide;
- and
- e) measuring the extent of cancer cell proliferation.
5 more elements
A method of measuring human cancer cell proliferation, comprising:
- a) providing:
- i) a human cancer patient,
- ii) an albumin-derived peptide, wherein said albumin-derived peptide is truncated, thereby shorter in length than the 585 amino acid long human serum albumin, and comprises domains I and II of human serum albumin;
- and
- iii) one or more hormones or hormone analogues;
- b) obtaining cancer cells from said patient;
- c) culturing said cells in serum-free culture media in the presence of said albumin-derived peptide and said one or more hormones or hormone analogues;
- and
- d) measuring cancer cell proliferation.
6 more elements
A method of measuring human cancer cell proliferation, comprising:
- a) providing:
- i) a human cancer patient,
- ii) an albumin-derived peptide, said peptide consisting of the N-terminal region of the 585 amino acid sequence of human serum albumin, said N-terminal region having the same amino acid sequence as said human serum albumin up to and including a terminal amino acid selected from the group consisting of amino acids 360-430 of said human serum albumin;
- b) obtaining cancer cells from said patient;
- c) culturing said cancer cells in serum-free media;
- d) contacting said cells ex vivo with said albumin-derived peptide;
- and
- e) measuring the extent of cancer cell proliferation.
5 more elements
Dependencies are inferred from the claim text.